轩竹生物-B（股票代码：02575）近日宣布，其核心产品宣愈宁比瑞西利片（Xuanyuening Bireociclib Tablets）的补充新药申请已获得监管机构批准，新增一项重要适应症。此次获批标志着该药物在临床应用范围的进一步拓展，有望为特定患者群体提供新的治疗选择。
比瑞西利片作为轩竹生物研发的创新药物，此次新适应症的获批将强化其在相关治疗领域的市场竞争力。公司表示，将积极推进该药物的商业化进程，以满足未竟的临床需求。
轩竹生物-B（股票代码：02575）近日宣布，其核心产品宣愈宁比瑞西利片（Xuanyuening Bireociclib Tablets）的补充新药申请已获得监管机构批准，新增一项重要适应症。此次获批标志着该药物在临床应用范围的进一步拓展，有望为特定患者群体提供新的治疗选择。
比瑞西利片作为轩竹生物研发的创新药物，此次新适应症的获批将强化其在相关治疗领域的市场竞争力。公司表示，将积极推进该药物的商业化进程，以满足未竟的临床需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.